Clinical Trial Update: IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing IMP321 (eftilagimod alpha) as an adjunct to paclitaxel in metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Breast

Drugs mentioned

• IMP321 (eftilagimod alpha)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Immutep S.A.S. | Conditions: Adenocarcinoma Breast Stage IV | Phase 2 | Status: COMPLETED